The clinical significance of interleukin 18 assessment in sarcoidosis patients

Kieszko, Robert; Krawczyk, Paweł; Jankowska, Olga; Chocholska, Sylwia; Król, Anna; Milanowski, Janusz

doi:10.1016/j.rmed.2006.08.019

Cited by 30 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interleukin (IL)-18, also called interferon (IFN)-cinducing factor, is an obligatory cytokine for IFN-c production [4] and plays a key role in the induction of Th1 responses [5]. Pro-IL-18 is a biologically inactive precursor that is produced during the acute immune response by monocytes, macrophages, and immature dendritic cells.…”

Section: Introductionmentioning

confidence: 99%

Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients

et al. 2009

View full text Add to dashboard Cite

Introduction Interleukin (IL)-18 plays an important dual role in Th1 polarization and viral clearance, as well as in the development of liver fibrosis. Single-nucleotide promoter polymorphisms influence the transcription of IL-18 mRNA. Promoter polymorphisms are linked to delayed virus clearance and disease susceptibility in many diseases. However, there is no information about their role in hepatitis C virus (HCV) infection. Aim To investigate the association between -607 or -137 polymorphism with susceptibility and severity of HCV infection. Patients and methods Two hundred and four serologically proven patients with chronic HCV infection and 350 matched healthy controls were included in this study. Patients were segregated in 2 groups: group A with mild liver disease and group B with severe liver disease on the basis of histological activity index (HAI B5 or [5) and hepatic fibrosis score (B2 or [2). IL-18 promoter genotyping was performed with sequence-specific primers. Results There was no significant difference in the frequencies of -607 and -137 allelic distribution in patients and controls. The -607 A/A allele was more common in group A patients with mild liver disease than in patients with severe liver disease on the basis of HAI (38.6% vs.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients

et al. 2009

View full text Add to dashboard Cite

show abstract

“…It is a very strong IFN-γ inducing factor. IL-18 level was the highest in plasma of patients with disease progression, in patients with lung interstitial changes and patients with extrapulmonary manifestation of the disease (Kieszko et al, 2007). Chitotriosidase, an enzyme secreted by activated macrophages and involved in defense against chitin-containing pathogens, was shown to correlate with the extent of lung changes, as assessed by radiological staging (Grosso et al, 2004).…”

Section: Other Immunological Markersmentioning

confidence: 98%

Prognostic Factors in Sarcoidosis

Piotrowski¹

2011

Sarcoidosis Diagnosis and Management

View full text Add to dashboard Cite

“…These cells release several chemokines and cytokines that lead to cellular proliferation. The cytokine profile of active BBS is characterized by T helper 1 (Th1) prevalence (Kieszko et al 2007). The main cytokine involved in the polarization of T-cell response is IL-18, an interferon gamma inducing factor (Kieszko et al 2007).…”

Section: Introductionmentioning

confidence: 99%

“…The cytokine profile of active BBS is characterized by T helper 1 (Th1) prevalence (Kieszko et al 2007). The main cytokine involved in the polarization of T-cell response is IL-18, an interferon gamma inducing factor (Kieszko et al 2007). Remodeling of lung tissues during the process of granuloma formation requires restructuring of the extracellular matrix and cathepsins K, L, and S are among the strongest extracellular matrix degrading enzymes (Samokhin et al 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endostatin and Cathepsin-V in Bronchoalveolar Lavage Fluid of Patients with Pulmonary Sarcoidosis

Naumnik

Ossolińska

Płońska

et al. 2014

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Recently, it has been reported that lack of cathepsins prevent the development of lung granulomas in a mouse model of Besnier-Boeck-Schaumann (BBS) disease, sarcoidosis. There is no data about cathepsin V (Cath V) in bronchoalveolar lavage fluid (BALF) in humans. Endostatin is a novel inhibitor of lung epithelial cells. The role of this protein in BBS is not determined. The aim of this study was to evaluate the concentration of endostatin, Cath V, and IL-18 in BALF of BBS patients. We studied 22 BBS patients (Stage 2). The control group consisted of 20 healthy subjects. Cath V concentration was lower in BBS than in healthy group (16.03±8.60 vs. 32.25±21.90 pg/ml, p=0.004). Both endostatin and IL-18 levels were higher in BBS than in the control group (0.88±0.30 vs. 0.29±0.04 ng/ml, p=0.028; 40.37±31.60 vs. 14.61±1.30 pg/ml, p=0.007, respectively). In BBS there were correlations between the levels of endostatin and IL-18 (r=0.74, p=0.001) as well as endostatin and DLCO (diffusing capacity for carbon monoxide) (r=-0.6, p=0.013). Receiver-operating characteristic (ROC) curves were applied to find the cut-off for the BALF levels of Cath V, endostatin, and IL-18. We conclude that Cath V and endostatin may represent an index of pulmonary sarcoidosis activity.

show abstract

The clinical significance of interleukin 18 assessment in sarcoidosis patients

Abstract: IL-18 may play a significant role in the prolongation of sarcoidosis course. Its estimation may become a good prognostic factor, which should be analyzed together with other factors useful in sarcoidosis monitoring.

Cited by 30 publications

References 24 publications

Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients

Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients

Prognostic Factors in Sarcoidosis

Endostatin and Cathepsin-V in Bronchoalveolar Lavage Fluid of Patients with Pulmonary Sarcoidosis

Contact Info

Product

Resources

About